Navigation Links
NuVasive to Host Investor Reception on September 11, 2007
Date:9/7/2007

Waldorf=Astoria Hotel New York City 5:30-7:30 p.m. (ET)

SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that it will host an investor reception for institutional investors and analysts at the Waldorf=Astoria Hotel in New York City on Tuesday, September 11, 2007, from 5:30 p.m. to 7:30 p.m. ET.

The reception will be hosted by NuVasive and includes presentations by senior management and top academic and private leading physicians from New York, Washington, DC and Texas. The physicians will participate in an interactive surgeon panel presentation covering key clinical updates, including an update from a surgeon participating in the NeoDisc clinical trial, as well as physician experience with XLIF(R) and new products launched during the first half of 2007 (SpheRx(R) II, XLP(TM) Lateral Plate and Formagraft(R)). Senior management and guest physicians will also participate in a question and answer session.

NuVasive senior management at the reception will include:

* Alex Lukianov, Chairman and Chief Executive Officer

* Keith Valentine, President and Chief Operating Officer

* Kevin O'Boyle, Executive Vice President and Chief Financial Officer

* Pat Miles, Executive Vice President of Marketing and Development

* Jeff Rydin, Senior Vice President, U.S. Sales

* Jason Hannon, Senior Vice President and General Counsel

Participants in the physician panel will include:

* Andrew Cappuccino, MD, Director Buffalo Spine Surgery and Assistant

Clinical Professor at SUNY, Buffalo, NY

* Randall Dryer, MD, Attending Orthopedic Surgeon, Central Texas Spine

Institute, Austin, TX

* Eric Elowitz, MD, Attending Neurosurgeon at St. Luke's-Roosevelt and

Beth Israel Hospitals and Assistant Professor of Neurological
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Venture Investors early-stage fund grows to $115 million
2. Investor warns of angel-venture funding gap
3. Brazilian bio-industry should impress American investors
4. Investors raise $25 million for biodiesel plant
5. Bio-energy and cleantech grab attention of investors
6. Venture Investors to open Michigan office
7. Early-stage executives hear from investors
8. Commerce qualifies seven for investor tax credits
9. Investor links East Coast funds to Midwest tech
10. Angel investors commit $12.7B in first half of `06
11. Wisconsin investors the lifeblood of New Jersey biotech

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , SAN MATEO, Calif., Nov. 24 /PRNewswire... biopharmaceutical company focused on developing a..., announced today that Anthony DiTonno, President ...nt at the 21st Annual Piper Jaffray Health Care Co... York Palace Hotel in New York, New York. ,, M...
(Date:11/24/2009)... , SEATTLE, Nov. 24 Blue Marb...nd the Odessa Public Development Authority (OPDA) ...te,s Community Economic Revitalization Board (CERB... state,s first specialty biochemical biorefinery i...l significantly speed the development of our biore...
(Date:11/24/2009)... , , Primary efficacy endpoint has been m...nt endometrial cancer, , QUEBEC CITY, Nov. 24...ASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global...erapy and oncology, today announced positive effic...totoxic peptide conjugate, AEZS-108 (formerly AN-1...
(Date:11/24/2009)... , DUBLIN, November 24 /PRNewswire-First...e global specialty biopharmaceutical company, toda...opean Medicines Agency for,velaglucerase alfa, the...nt,for the treatment of Type 1 Gaucher disease. Th...erase alfa that has been submitted, with previous,...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4
...BOLZANO, Italy, April 14 Health Robotics today an... 31, 2008, delivering record levels,of firm purcha...Revenues in FY2008 were EUR8.2 million, a 161% inc...d and enjoy the benefits of its indirect,sales-cha...ition, zero debt,financing, worldwide adoption of ...
... Virus-like Particle (VLP) Vaccine Candidate Based...ce and Ferrets Against the Spanish Flu and Highly ...ril 14 /PRNewswire-FirstCall/ -- Novavax, In...udy results showing that an investigational H1N1 v... Spanish influenza strain protected against both t...
...JOSEPH, Mich., April 14 GeneGo, Inc., the leading...at Professor Marcelo Bento Soares of Children,s Me...Stem Cell Partnership Program. The goal of the pr...maps for adult, embryonic, fetal, fibroblasts, hem...pluripotent and totipotent stem cells. , , "We fe...
Other Biology Technology:Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 2Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 3Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 4Health Robotics Reports Triple-Digit-Growth Across All Financial Metrics in Fiscal Year 2008 5NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 2NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 3NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 4NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains 5Children's Memorial Research Center, Chicago Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program 2
(Date:11/25/2009)...rofessors recently received funding from the Natio...beneficial to understanding the environment. The t...ood, assistant professor in the Department of Biol... separate research projects. , His first project... and Functions from the Leaf to the Landscape," wi...
(Date:11/24/2009)...escribed by traditional healers in Brazil to treat...in to fever and flu. , Now for the first time, re...o scientifically prove the pain relieving properti...an mint. , Testing this ancient South American he...cha was able to show that when prepared as a ,tea,...
(Date:11/24/2009)...o understanding how sounds associated with Navy so...r if they hear it at all. , The same type of lar...to detect flaws in the space shuttle,s behemoth so...k inside the giant head of a whale. The scans are ... whale,s hearing anatomy using a breakthrough meth...
Breaking Biology News(10 mins):Kent State University professors focus research on the environment with grants totaling $890,000 2Got a pain? -- Have a cup of Brazilian mint 2Rocket science leads to new whale discovery 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec 28R 29 for the Treatment of Chronic Gastrointestinal GVHD 13343 1DOR BioPharma Receives FDA Orphan Drug Designation for orBec 28R 29 for the Treatment of Chronic Gastrointestinal GVHD 13343 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec 28R 29 for the Treatment of Chronic Gastrointestinal GVHD 13343 3DOR BioPharma Receives FDA Orphan Drug Designation for orBec 28R 29 for the Treatment of Chronic Gastrointestinal GVHD 13343 4DOR BioPharma Receives FDA Orphan Drug Designation for orBec 28R 29 for the Treatment of Chronic Gastrointestinal GVHD 13343 5DOR BioPharma Receives FDA Orphan Drug Designation for orBec 28R 29 for the Treatment of Chronic Gastrointestinal GVHD 13343 6High cholesterol in midlife raises risk of late life dementia Kaiser Permanente study finds 53591 1High cholesterol in midlife raises risk of late life dementia Kaiser Permanente study finds 53591 2High cholesterol in midlife raises risk of late life dementia Kaiser Permanente study finds 53591 3Motorcyclist Lives On Rides On Through Organ Donation 53587 1Motorcyclist Lives On Rides On Through Organ Donation 53587 2Motorcyclist Lives On Rides On Through Organ Donation 53587 3Motorcyclist Lives On Rides On Through Organ Donation 53587 4Motorcyclist Lives On Rides On Through Organ Donation 53587 5
...ray-on films developed by UC San Diego chemists wi...ly reveal trace amounts of nitrogen-based explosiv...s on the films, which glow blue under ultraviolet ...fferent classes of explosive chemicals, a property..., or prevent one. , A recent episode of CSI: Miam...
...ing to a report from a CSIRO Wealth From Oceans Fl...ournal Geophysical Research Letters since 1950 Vi...n rainfall (March to May) compared to the average ...SIROs Dr Wenju Cai and Tim Cowan, say that the dec...s for about half of the total seasonal reduction.,...
... 25, 2008, approaching 5 p.m. PDT, NASA scientists...? , That,s because at that time the Phoenix Mars ... three legs to make a soft landing onto the northe... no valley is actually green on the Red Planet. Th... Mars Reconnaissance Orbiter,s HiRISE instrument. ...
Other Biology News:Glowing films developed by UC San Diego chemists reveal traces of explosives 2Understanding autumn rain decline in SE Australia 2Phoenix mission to Mars will search for climate clues 2Phoenix mission to Mars will search for climate clues 3
Hae III (High Concentration) from Takara Mirus Bio
2 ml SmartScan Racks from ABgene
Rabbit Anti-Leptin Receptor Polyclonal Antibody, Unconjugated from BioVision
...wer supply. Capable of producing up to 500 volts a...AGE, SDS-PAGE, DNA or RNA submarine gels as well a... is designed to operate in constant voltage or con...in either mode. The EC135-90 automatically crosses...
Biology Products: